Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

8.8K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
8.8K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

3.1K
3.1K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

2.7K
2.7K
Inflammation01:38

Inflammation

62.2K
Overview
62.2K
Cooperative Binding of Transcription Regulators02:13

Cooperative Binding of Transcription Regulators

7.4K
Transcriptional regulators bind to specific cis-regulatory sequences in the DNA to regulate gene transcription. These cis-regulatory sequences are very short, usually less than ten nucleotide pairs in length. The short length means that there is a high probability of the exact same sequence randomly occurring throughout the genome.  Since regulators can also bind to groups of similar sequences, this further increases the chances of random binding. Transcriptional regulators form...
7.4K
Mutations01:39

Mutations

94.5K
Overview
94.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multispecialty referral patterns to a clonal hematopoiesis clinic: Who, what, and why?

Leukemia research·2026
Same author

L1CAM signaling through planar cell polarity drives SOX2 expression and lung adenocarcinoma metastasis.

Nature communications·2026
Same author

Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity.

Cancer cell·2026
Same author

Characterization of subclonal variants in HG002 Genome in a Bottle reference material as a resource for benchmarking variant callers.

Cell genomics·2025
Same author

Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia.

Cancer discovery·2025

Related Experiment Video

Updated: Feb 7, 2026

Isolation of Intrapulmonary Artery and Smooth Muscle Cells to Investigate Vascular Responses
07:56

Isolation of Intrapulmonary Artery and Smooth Muscle Cells to Investigate Vascular Responses

Published on: June 8, 2022

4.8K

TET2 and TP53 Mutations Cooperatively Modulate the Response to Inflammation to Promote Leukemic Transformation.

Pablo Sánchez Vela, Brianna Kelly, Claudia Brady

    Biorxiv : the Preprint Server for Biology
    |February 6, 2026
    PubMed
    Summary

    Mutations in TET2 and TP53 genes cooperate to drive hematologic malignancies. TP53 mutations enable cells to tolerate inflammation, promoting disease progression and altering chemotherapy response.

    More Related Videos

    Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
    08:44

    Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

    Published on: May 30, 2020

    6.6K
    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
    07:05

    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

    Published on: February 23, 2024

    3.8K

    Related Experiment Videos

    Last Updated: Feb 7, 2026

    Isolation of Intrapulmonary Artery and Smooth Muscle Cells to Investigate Vascular Responses
    07:56

    Isolation of Intrapulmonary Artery and Smooth Muscle Cells to Investigate Vascular Responses

    Published on: June 8, 2022

    4.8K
    Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
    08:44

    Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

    Published on: May 30, 2020

    6.6K
    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
    07:05

    Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

    Published on: February 23, 2024

    3.8K

    Area of Science:

    • Hematology
    • Cancer Biology
    • Genetics

    Background:

    • * TET2 mutations are common in hematologic malignancies and clonal hematopoiesis (CH), affecting stem cell function and inflammation.
    • * TP53 mutations frequently co-occur with TET2 mutations in high-risk CH and hematologic malignancies.

    Purpose of the Study:

    • * To investigate the cooperative effects of TET2 and TP53 mutations in a murine model.
    • * To understand the mechanisms driving disease progression and identify therapeutic targets.

    Main Methods:

    • * Utilized a murine model of hematopoietic stem and progenitor cells (HSPCs) with dual TET2 and TP53 mutations.
    • * Analyzed genomic alterations, disease phenotypes, inflammatory signatures, and cell death pathways.
    • * Investigated the role of NLRP1 in TP53-mediated stress response.

    Main Results:

    • * Dual mutant HSPCs initially showed a myeloproliferative phenotype, progressing to acute leukemias including B-ALL.
    • * Enhanced inflammatory signatures were observed during transformation.
    • * Identified NLRP1 as a TP53 target, with TP53 mutations conferring tolerance to inflammatory stress.
    • * Demonstrated altered response to chemotherapy-induced protein translational stalling.

    Conclusions:

    • * TET2 and TP53 mutations cooperate to drive hematologic malignancy development and progression.
    • * TP53-mediated tolerance to inflammatory stress is a key mechanism in disease adaptation.
    • * The identified stress response pathway impacts chemotherapy tolerance, suggesting potential therapeutic strategies.